CoChat

Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial

Mathieu, Chantal, Zinman, Bernard, Hemmingsson, Joanna Uddén, Woo, Vincent, Colman, Peter, Christiansen, Erik, Linder, Martin, Bode, Bruce, for the ADJUNCT ONE Investigators · 2016 · Diabetes Care

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To investigate whether liraglutide added to treat-to-target insulin improves glycemic control and reduces insulin requirements and body weight in subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS: A 52-week, double-blind, treat-to-target trial involving 1,398 adults randomized 3:1 to receive once-daily subcutaneous injections of liraglutide (1.8, 1.2, or 0.6 mg) or placebo added to insulin. RESULTS: HbA1c level was reduced 0.34–0.54% (3.7–5.9 mmol/mol) from a mean baseline of 8.2% (66 mmol/mol), and significantly more for liraglutide 1.8 and 1.2 mg compared with placebo (estimated treatment differences [ETDs]: 1.8 mg liraglutide −0.20% [95% CI −0.32; −0.07]; 1.2 mg liraglutide −0.15% [95% CI −0.27; −0.03]; 0.6 mg liraglutide −0.09% [95% CI −0.21; 0.03]). Insulin doses were reduced by the addition of liraglutide 1.8 and 1.2 mg versus placebo (estimated treatment ratios: 1.8 mg liraglutide 0.92 [95% CI 0.88; 0.96]; 1.2 mg liraglutide 0.95 [95% CI 0.91; 0.99]; 0.6 mg liraglutide 1.00 [95% CI 0.96; 1.04]). Mean body weight was significantly reduced in all liraglutide groups compared with placebo ETDs (1.8 mg liraglutide −4.9 kg [95% CI −5.7; −4.2]; 1.2 mg liraglutide −3.6 kg [95% CI −4.3; −2.8]; 0.6 mg liraglutide −2.2 kg [95% CI −2.9; −1.5]). The rate of symptomatic hypoglycemia increased in all liraglutide groups (estimated rate ratios: 1.8 mg liraglutide 1.31 [95% CI 1.07; 1.59]; 1.2 mg liraglutide 1.27 [95% CI 1.03; 1.55]; 0.6 mg liraglutide 1.17 [95% CI 0.97; 1.43]), and hyperglycemia with ketosis increased significantly for liraglutide 1.8 mg only (event rate ratio 2.22 [95% CI 1.13; 4.34]). CONCLUSIONS: Liraglutide added to insulin therapy reduced HbA1c levels, total insulin dose, and body weight in a population that was generally representative of subjects with type 1 diabetes, accompanied by increased rates of symptomatic hypoglycemia and hyperglycemia with ketosis, thereby limiting clinical use in this group.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc16-0691

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 347

Metadata

Authors
Mathieu, C., Zinman, B., Hemmingsson, J. U., Woo, V., Colman, P., Christiansen, E., Linder, M., Bode, B., & for the ADJUNCT ONE Investigators
Affiliations
  • Universitair Ziekenhuis Leuven (BE)
  • Mount Sinai Hospital (CA)
  • Capio St. Görans Hospital and the Karolinska Institute, Stockholm, Sweden
  • Health Sciences Centre (CA)
  • The Royal Melbourne Hospital (AU)
  • Novo Nordisk (Denmark) (DK)
  • Atlanta Diabetes Associates (US)
Corresponding author
Mathieu, Chantal
Venue
Diabetes Care
Published
2016-08-09
Volume
39
Issue
10
Pages
1702-1710
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2514658869
Cited by
347
References
26
Citations by year
2026: 52 · 2025: 56 · 2024: 49 · 2023: 28 · 2022: 23 · 2021: 28 · 2020: 34 · 2019: 27 · 2018: 26 · 2017: 17 · 2016: 7
FWCI
25.77
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
  • Lirias (submittedVersion)
Funders
Novo Nordisk A/S (NN9211-3919)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
liraglutide, type 1 diabetes, insulin therapy, glycemic control, HbA1c, insulin dose reduction, weight loss, GLP-1 receptor agonists, adjunctive therapy, drug safety, hypoglycemia, nausea, gastrointestinal adverse effects, drug discontinuation
MeSH terms
Liraglutide, Adult, Diabetes Mellitus, Type 1, Double-Blind Method, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Male, Middle Aged, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.